Prognostic impact of extranodal extension in oral cavity cancers: a retrospective analysis and implications for treatment intensification

淋巴结外侵犯对口腔癌预后的影响:一项回顾性分析及其对强化治疗的意义

阅读:1

Abstract

PURPOSE: Extranodal extension (ENE) and positive surgical margins are recognized high-risk factors in head and neck cancers. Despite their prognostic significance, ENE was incorporated into the AJCC 8th edition staging only recently. This study evaluates survival outcomes in patients with oral cavity squamous cell carcinoma (OCSCC) based on ENE status and its association with radiological ENE and other intermediate-risk features, including lymphovascular invasion (LVI), perineural invasion (PNI), T stage, and depth of infiltration (DoI). METHODS: We retrospectively analyzed 198 patients with OCSCC treated between 2015 and 2022 with surgery followed by adjuvant radiotherapy (60 Gy in 30 fractions), with or without concurrent chemotherapy. Chemotherapy was administered in cases with ENE or margin positivity. Patients were followed at 3-month intervals with clinical evaluations and imaging as indicated. Kaplan-Meier analysis was used to estimate overall survival (OS) and disease-free survival (DFS). Differences between groups were assessed using the log-rank test, and univariate and multivariate Cox regression analyses identified prognostic factors. RESULTS: The mean age was 55 ± 12 years, with 86.4% male patients. The buccal mucosa (61.6%) was the most common subsite. After a median follow-up of 36 months, the 3-year OS and DFS rates were 56.0% and 53.1%, respectively. Patients with pathological ENE had significantly worse outcomes: 3-year DFS was 34.7% vs. 68.6% (HR: 0.303; p < 0.001), and OS was 35.3% vs. 74.0% (HR: 0.270; p < 0.001). Radiological node positivity, LVI, and PNI were also independently associated with poorer survival. CONCLUSION: ENE significantly worsens OS and DFS in OCSCC patients, even with standard adjuvant chemoradiotherapy. These findings support the need for treatment intensification strategies, such as radiation dose escalation and/or additional systemic therapy, in this high-risk group.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。